Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carmen Benasco is active.

Publication


Featured researches published by Carmen Benasco.


The American Journal of Gastroenterology | 2001

Efficacy of interferon for chronic hepatitis C virus–related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation

Teresa Casanovas-Taltavull; Carme Baliellas; Carmen Benasco; Teresa Serrano; Aurora Casanova; José Luis Pérez; Lourdes Guerrero; M Teresa González; Enric Andres; Salvador Gil-Vernet; Luis Casais

OBJECTIVES:Interferon-α (IFN) may have undesirable effects on a functioning graft. The aim of this study was to evaluate IFN treatment in kidney transplant candidates during the hemodialysis period as well as the results after transplantation.METHODS:A total of 29 noncirrhotic hemodialysis patients with chronic hepatitis C virus (HCV) infection (based on long-term rise in ALT, HCV serology, HCV RNA by polymerase chain reaction methods, and histological evidence) were included. Tolerability to IFN treatment, pre- and posttransplantation therapeutic results, and long-term outcome were recorded. IFN regimen consisted of 3 million units (MU) times per week after hemodialysis sessions for 6 months, followed by 1.5 MU after each hemodialysis session for an additional 6 months. All patients gave informed consent for participation.RESULTS:IFN therapy was fairly well tolerated. Adverse effects due to IFN toxicity, renal disease, or causes related to the immunological properties of IFN were observed in 24% of patients. At the end of treatment, ALT had normalized in 23/28 patients (82.1%), and HCV RNA had cleared in 23/28 patients (82.1%). During follow-up, HCV RNA was persistently negative in 18 patients (64%, including transplant recipients). A total of 14 patients (nine HCV RNA–negative) received a kidney transplant. Mean follow-up after the procedure was 41 ± 28 months. In all, 12 patients had a functioning graft, one had acute vascular rejection, and one died of carcinoma. All transplanted patients maintained normal ALT levels, and eight remained HCV RNA–negative.CONCLUSIONS:Treatment results in our study population were better than those observed in the general population. The long-term response achieved, which was maintained after transplantation, supports the use of IFN for HCV hepatitis in kidney transplant candidates under hemodialysis.


Cancer | 1987

Human chorionic gonadotropin in colorectal carcinoma. An immunohistochemical study.

Elias Campo; Antonio Palacín; Carmen Benasco; Enrique Quesada; Antonio Cardesa

To assess the biological significance of human chorionic gonadotropin (HCG) detection in large bowel carcinomas, we have studied immunohistochemically 50 colorectal carcinomas, 20 adenomas, 8 ulcerative colitis, and 10 normal colonic mucosae. The HCG‐immunoreactive cells were found in 26 carcinomas (52%). Positivity was not detected in any normal mucosa or benign lesions. Cells containing HCG predominated in mucinous (80%) and poorly differentiated carcinomas (92%). No trophoblastic differentiation could be demonstrated in any tumor. Human chorionic gonadotropin was detected more frequently in carcinomas invading the entire bowel wall (67%) than in those confined to the submucosa or muscularis propria (30%). Fifteen of 19 cases (79%) with lymph node and/or hepatic metastases had HCG in the primary tumor, whereas only 9 of 23 cases (32%) without metastases showed HCG immunoreactivity. The eight patients with hepatic metastases had HCG in the primary tumor. Thus, the immunohistochemical detection of HCG in colorectal carcinomas may be a biological marker of prognostic significance.


Medicina Clinica | 2000

Análisis de 500 trasplantes hepáticos en el Hospital de Bellvitge

Eduardo Jaurrieta; Luis Casais; Juan Figueras; Emilio Ramos; C Lama; Antonio Rafecas; Teresa Casanovas Taltavull; Juan Fabregat; Xavier Xiol; Jaume Torras; C. Baliellas; A Sabate; Gabriel Rufi; Carmen Benasco; Teodoro Casanovas; Teresa Serrano; Salvador Gil-Vernet; Isabel Sabaté; Juli Busquets

Fundamento Se presenta la experiencia del programa de trasplante hepatico del Hospital de Bellvitge en 500 trasplantes realizados durante 15 anos, con el objetivo de poner de manifiesto los cambios que se han producido y exponer los resultados a largo plazo de esta terapeutica. Pacientes y metodo Se consideraron y compararon 5 grupos de 100 trasplantes consecutivos (I-V). Resultados Las indicaciones mas frecuentes fueron el hepatocarcinoma (23%), la cirrosis alcoholica (22,8%) y la hepatopatia cronica por virus C (18,8%). En 59 pacientes se llevaron a cabo 65 retrasplantes (13%), cuyas indicaciones mas frecuentes fueron la trombosis arterial (13 pacientes) y el fallo primario del injerto (10 pacientes). En 19 enfermos se realizo un trasplante combinado hepatorrenal. La causa mas frecuente de muerte del donante en el grupo I fueron los traumatismos craneales (80%), mientras que en el grupo V fue la enfermedad vascular (52%). Otras diferencias significativas entre estos grupos se observan en la proporcion de pacientes en estadio 2 y 3 de la clasificacion UNOS (el 45 frente al 19%), en el consumo de hemoderivados (29,6 [26] frente a 4,6 [5,3] concentrados de hematies), en la frecuencia de reintervenciones por hemoperitoneo (el 22 frente al 5%), en la estancia en UCI (13 [13] frente a 7,4 [11] dias) y en el hospital 40 [52] frente a 23,7 [17] dias), y en la incidencia de rechazo (el 46 frente al 20%) y de fallo primario del injerto (el 9 frente al 3%). Sin embargo, la prevalencia de infeccion (el 48 frente al 54,5%) y la incidencia de complicaciones biliares (el 26 frente al 20%) no han presentado variaciones significativas. La supervivencia actuarial de los pacientes trasplantados desde 1990 es del 83 y del 70% al ano y a los 5 anos, respectivamente. Conclusiones Se observa una mejoria notable y progresiva de los resultados del trasplante hepatico. Sin embargo, los tumores de novo, la recidiva de la hepatitis por virus C y el rechazo cronico pueden limitar los resultados a largo plazo.


European Radiology | 1994

Computed tomography after Lipiodol chemoembolization in hepatocellular carcinoma

Carlos Valls; Joan-Josep Pamies; Concha Sancho; Carmen Benasco; Joan Figueras; Joan Dominguez; Eduardo Jaurrieta; Xavier Montaña

In order to ascertain the patterns of Lipiodol uptake and the diagnostic value of Lipiodol-CT in hepatocellular carcinoma (HCC), we present a retrospective analysis of CT and histological findings after Lipiodol chemoembolization. After chemoembolization 22 consecutive patients with H HCC wer studied with CT and pathological cor relat ion was available in all cases. Two patterns of Lipiodol uptake were defined: nodular (with complete or incomplete Lipiodol retention) and diffuse pattern. Lipiodol-CT demonstrated all principal tumors and 7 satellite CT lesions in 16 cases of nodular pattern, while 13 satellite lesions were not detected. Significant tumor necrosis (mean necrotic rate >90 %) was detected in 13cases of nodular pattern with complete Lipiodol retention. No significant necrosis was present in nodular pattern with incomplete retention, nor in diffuse pattern. Lipiodol-CT remain, an important diagnostic cool in presurgical evaluation of HCC, although some satellite lesions remain undetected. Nodular pattern correlates well with significant necrosis, but diffuse pattern does not.


Pathology Research and Practice | 1991

Human chorionic gonadotropin in esophageal carcinomas. An immunohistochemical study.

I. Trias; Elias Campo; Carmen Benasco; Antonio Palacín; Antonio Cardesa

We have examined immunohistochemically the presence of human chorionic gonadotrophin (hCG) in 29 esophageal carcinomas: 24 squamous cell carcinomas, 2 adenocarcinomas, 2 adenoid cystic carcinomas and 1 adenosquamous carcinoma. In hCG-positive tumors, the presence of human placental lactogen (hPL) and pregnancy-specific beta-1 glycoprotein (SP-1) was also assessed. HCG immunoreactive cells were found in 5 squamous cell carcinomas (21%) and in none of 5 non-squamous cell tumors. The hCG positive cells were found in the most infiltrating areas of the tumors where poorly differentiated and pleomorphic cells predominated. The positive tumors were 4 poorly differentiated (31%) and one moderately differentiated carcinoma (12%). Four out of 10 cases (40%) with lymph node metastases had hCG in the primary tumor, whereas only one out of 11 cases (9%) without metastases was hCG positive. HPL and SP-1 were found in two cases. These placental proteins were detected in similar areas than hCG but the number of hPL and SP-1 immunoreactive cells was lower than hCG positive cells. SP-1 was also seen in areas of squamous cell differentiation negative for hCG. None of these two cases showed trophoblastic differentiation.


International Journal of Biological Markers | 1987

Ferritin Immunohistochemical Localization in Normal and Neoplastic Colonic Mucosa

Elias Campo; Antonio Palacín; Carmen Benasco; Enric Condom; Antonio Cardesa

High levels of ferritin have been detected in serum and tumoral extracts of gastrointestinal neoplasms. However, its histological localization is not well known. An immunoperoxidase technique (PAP) was used for detecting ferritin in 30 colorectal carcinomas, 20 polyps and 8 cases of non-neoplastic mucosae. Ferritin staining was detected in stromal cells (98%) much more than in epithelial cells (21%). Connective cells were positive in 5 cases of normal mucosae (62%), 19 polyps (95%) and all carcinomas (100%). The number of positive cells gradually rose from normal mucosa to carcinoma with an intermediate score in adenomas. However, no relation could be found between the stromal ferritin score and dysplasia in polyps. Likewise, no relation was found between the stromal ferritin score and the differentiation grade, invasion or metastases in carcinomas. The positive epithelial pattern seen in 12 cases (21%) suggests non-specific staining due to passive diffusion from the stroma. Thus, these immunohistochemical findings suggest that in colonic neoplasms, ferritin could be a tumor marker produced mainly by stromal cell reaction more than by the epithelial cells.


Archive | 1996

«De Novo» Carcinoma after Liver Transplant (L.T.)

T. Casanovas Taltavull; C. Baliellas; M. Sánchez Gili; Aurora Casanova; Carmen Benasco; Juan Fabregat; Antonio Rafecas; Juan Figueras; Salvador Gil-Vernet; Eduardo Jaurrieta; Luis Casais

Patients who have received a L.T. have a higher risk of developing «de novo» neoplasia than the general population.


Archive | 1996

HCV Chronic Infection in HD (Hemodialysed) Candidates to KT (Kidney Transplant). Influence of Virus C Genotypes on Response to IFN Treatment

T. Casanovas Taltavull; C. Baliellas; A. Perelló; X. Cervantes; Carmen Benasco; E. Andrés; M. T. González; Salvador Gil-Vernet; J. L. Pérez; J. Niubó; Aurora Casanova; Luis Casais

IFN is the most accepted treatment for HCV chronic infection in immunocompetent patients. But IFN is not without risk in transplanted patients, because possible deleterious effects on the graft.


Hepatology | 1997

Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study.

Juan Figueras; Eduardo Jaurrieta; Carlos Valls; Carmen Benasco; Antonio Rafecas; Xavier Xiol; Joan Fabregat; Teresa Casanovas; Joan Torras; C. Baliellas; L Ibañez; P Moreno; Luis Casais


Catalan Transplantation Society. International congress | 1995

Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant.

T. Casanovas Taltavull; C. Baliellas; E. Sese; M. J. Iborra; Carmen Benasco; E. Andres; M. T. Gonzalez; Salvador Gil-Vernet; Aurora Casanova; Luis Casais

Collaboration


Dive into the Carmen Benasco's collaboration.

Top Co-Authors

Avatar

Luis Casais

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

C. Baliellas

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elias Campo

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge